ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Signal Amplification by Reversible Exchange for COVID-19 Antiviral Drug Candidates_2e.pdf (1.24 MB)
0/0

Signal Amplification by Reversible Exchange for COVID-19 Antiviral Drug Candidates

preprint
revised on 06.04.2020 and posted on 08.04.2020 by HyeJin Jeong, Sein Min, Heelim Chae, Sara Kim, Gunwoo Lee, Sung Keon Namgoong, Keunhong Jeong

Several drug candidates have been proposed and tested as the latest clinical treatment for the coronavirus pneumonia (COVID-19). Chloroquine, hydroxychloroquine, ritonavir/lopinavir, and favipiravir are proved to be effective after treatment. The hyperpolarization technique presents an ability to further understand the roles of these drugs at the molecular scale and applications in nuclear magnetic resonance/magnetic resonance imaging (NMR/MRI). This technique may provide new opportunities in diagnosis and biomedical research to cope with COVID-19. Signal amplification by reversible exchange (SABRE)-based hyperpolarization studies on large-sized drug candidates were carried out. We observed hyperpolarized proton signals from whole structures, due to the unprecedented long-distance polarization transfer by para-hydrogen. We also found that the optimum magnetic field for the maximum polarization transfer yield was dependent on the molecular structure. Therefore, future research on isotope labelling and polarization transfer on long T1 time nuclei including clinical perspectives can help us overcome this worldwide pandemic.

Funding

National Research Foundation of Korea

History

Email Address of Submitting Author

doas1mind@kma.ac.kr

Institution

Korea Military Academy

Country

South Korea

ORCID For Submitting Author

0000-0003-1485-7235

Declaration of Conflict of Interest

The Authors declare that there is no conflict of interest.

Exports